Side Effects

Hormones Clinical Studies Weight Loss Culture Adverse Effects Medication Risks Research Studies Pharmacology Patient Care Medical Conditions FDA

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

The phase 1 data reveal sustained weight reduction with tolerable gastrointestinal effects ahead of planned 2026 phase 3 trials.

FDA Warns of Rare Severe Itching After Stopping Common Allergy Medications

UK Government Proposes Pharmacy Access for Weight-Loss Jabs Amid Rising Demand

Widespread Use of Weight-Loss Drugs Redefines Health, Beauty, and Access